SEC Comment Letter 0000000000-23-007858 to Clearmind Medicine Inc. (CMND)
Clearmind Medicine Inc.
Date: July 24, 2023 · CIK: 0001892500 · Accession: 0000000000-23-007858
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273293
Letter
United States securities and exchange commission logo July 24, 2023 Adi Zuloff-Shani, Ph.D. Chief Executive Officer Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 Re:Clearmind Medicine Inc. Registration Statement on Form F-1 Filed July 17, 2023 File No. 333-273293 Dear Adi Zuloff-Shani: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David A. Huberman
Show Raw Text
United States securities and exchange commission logo
July 24, 2023
Adi Zuloff-Shani, Ph.D.
Chief Executive Officer
Clearmind Medicine Inc.
101 – 1220 West 6th Avenue
Vancouver, British Columbia V6H1A5
Re:Clearmind Medicine Inc.
Registration Statement on Form F-1
Filed July 17, 2023
File No. 333-273293
Dear Adi Zuloff-Shani:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David A. Huberman